sema4e Antibody

What is Semaphorin 4D and what are its primary cellular receptors?

Semaphorin 4D (SEMA4D or CD100) is a member of the semaphorin family of proteins that functions as an important mediator of movement and differentiation across multiple cell types, including immune, vascular, and nervous systems. SEMA4D interacts with three primary cellular receptors:

• PLXNB1 (plexin-B1): The highest-affinity receptor for SEMA4D

• PLXNB2 (plexin-B2): Another plexin family receptor that binds SEMA4D

• CD72: A receptor predominantly expressed on immune cells

These receptor interactions mediate different biological functions depending on the cellular context. In immune cells, SEMA4D-CD72 interaction leads to the dissociation of the tyrosine phosphatase SHP-1, removing a negative regulatory signal in B cells. This helps explain SEMA4D's role in enhancing antibody responses and immune cell function .

How is SEMA4D expressed in normal tissues and disease states?

SEMA4D is abundantly expressed on the surface of most lymphocytes, with T cells expressing the highest levels. Expression patterns vary by cell type and activation state:

• T cells: Highest baseline expression that increases upon activation

• B cells: Upregulation upon cellular activation

• Dendritic cells (DCs): Increased expression following activation

• Monocytes and macrophages: Moderate expression

• Platelets: Low baseline expression that increases with platelet activation

• Oligodendrocytes: Upregulation upon injury

In disease states, SEMA4D is frequently overexpressed. It is present at elevated levels in multiple sclerosis (MS) patient sera (27.4 ng/ml compared to 10.4 ng/ml in normal human sera) . In cancer, immunohistochemical analysis has shown SEMA4D overexpression in head and neck, prostate, colon, breast, and lung cancers, with elevated expression correlating with invasive disease and poor prognosis .

What are the functional differences between membrane-bound and soluble SEMA4D?

SEMA4D exists in both membrane-bound and soluble forms, each with distinct functional properties:

Membrane-bound SEMA4D:

• Primarily expressed on immune cells, especially T lymphocytes

• Mediates cell-cell contact-dependent signaling

• Contributes to immune synapse formation

Soluble SEMA4D (sSEMA4D):

• Generated through proteolytic cleavage of the extracellular domain following cellular activation

• Acts as a diffusible factor that can mediate effects at a distance

• Inhibits immune cell migration in certain contexts

• Can accelerate in vivo antibody responses

• Elevated in disease states such as multiple sclerosis

The transition from membrane-bound to soluble SEMA4D represents an important regulatory mechanism that modifies the range and type of signaling that can occur in different physiological and pathological contexts.

What methodological approaches are used to assess SEMA4D antibody specificity and binding characteristics?

Comprehensive characterization of anti-SEMA4D antibodies requires multiple complementary techniques to assess specificity, affinity, and cross-reactivity. Based on the methodologies used for VX15/2503 characterization, researchers should consider these approaches:

• ELISA-based assays:

  • Direct binding to recombinant and native SEMA4D

  • Competition assays to determine epitope specificity

  • Reactivity testing against irrelevant proteins to confirm specificity

• Flow cytometry-based assays:

  • Binding to SEMA4D-expressing cells across different species

  • Cell-based affinity determination

  • Receptor blocking assays to measure functional potency

• Surface plasmon resonance (Biacore):

  • Quantitative determination of binding kinetics

  • Measurement of equilibrium dissociation constant (KD)

  • Comparative analysis across species variants of SEMA4D

• Immunohistochemistry:

  • Tissue reactivity profiling

  • Specificity confirmation using SEMA4D-deficient tissues

For the humanized antibody VX15/2503, these methodologies demonstrated high specificity for SEMA4D with KD values ranging from 1-5 nM for recombinant antigen and approximately 0.45 nM for native cell-associated human SEMA4D .

How can researchers develop antibodies that cross-react with SEMA4D across multiple species for preclinical studies?

Developing cross-reactive antibodies to SEMA4D presents unique challenges due to evolutionary conservation and immune tolerance. The successful generation of VX15/2503 provides an instructive methodological approach:

• Immunization strategy:

  • Use SEMA4D-knockout mice to bypass self-tolerance mechanisms

  • This approach successfully generated approximately 96 parental hybridomas with cross-reactivity to both mouse and human SEMA4D

• Selection criteria:

  • Screen for binding to SEMA4D from multiple species (mouse, rat, rabbit, cynomolgus macaque, marmoset, rhesus macaque, and human)

  • Prioritize clones with consistent affinity across species

  • Confirm functional blocking activity

• Humanization process:

  • Transfer complementarity-determining regions (CDRs) from the mouse antibody to a human IgG4 framework

  • Maintain cross-reactivity properties through the humanization process

  • Verify that species cross-reactivity is preserved after humanization

This approach successfully yielded VX15/2503, which demonstrates consistent binding across species with KD values ranging from 1.5-5.1 nM across mouse, rat, cynomolgus macaque, and human SEMA4D as shown in Table 1 .

Table 1: SEMA4D Affinity (KD, nM) Across Species

ND = Not Determined. Affinity values measured by Biacore using whole antibodies; values represent mean of minimum triplicates for each measurement.

What functional assays are essential for evaluating the mechanism of action of anti-SEMA4D antibodies?

To comprehensively characterize anti-SEMA4D antibodies, researchers should employ multiple functional assays that assess both desired blocking activity and potential unwanted effects:

• Receptor blocking assays:

  • Flow cytometry-based assays measuring inhibition of SEMA4D binding to PLXNB1, PLXNB2, and CD72

  • Quantitative determination of EC50 values for blocking activity

  • The potency release assay for VX15/2503 measured PLXNB1 blocking with a mean EC50 of 1.2 nM

• Effector function assays:

  • Complement-dependent cytotoxicity (CDC) assays to assess unwanted cell killing

  • Antibody-dependent cell-mediated cytotoxicity (ADCC) assays using SEMA4D-positive target cells

  • For therapeutic antibodies like VX15/2503, these assays should confirm minimal effector function to avoid depletion of SEMA4D-expressing immune cells

• In vivo functional studies:

  • Tumor growth inhibition in transplanted and orthotopic models

  • Assessment of tumor angiogenesis

  • Evaluation of immune cell infiltration into tumors

  • Studies in SEMA4D-knockout animals to confirm specificity

• Antibody stability assays:

  • Assessment of half-antibody formation

  • For IgG4 antibodies like VX15/2503, evaluation of the S241P hinge modification to prevent formation of bispecific antibodies in vivo

  • ELISA-based detection of potential bispecific antibodies

These assays provide critical information about both the potency and safety of anti-SEMA4D antibodies, guiding their development for therapeutic applications.

What is the rationale for targeting SEMA4D in cancer immunotherapy?

The scientific rationale for targeting SEMA4D in cancer immunotherapy is multi-faceted and involves several mechanisms documented in preclinical studies:

• Disruption of the immunosuppressive tumor microenvironment:

  • SEMA4D expression at the invasive tumor edge creates a barrier to immune infiltration

  • Anti-SEMA4D antibody treatment facilitates access and amplification of anti-tumor immune activity within the tumor

  • Blocking SEMA4D increases immune cell infiltration into the tumor microenvironment

• Inhibition of tumor angiogenesis:

  • SEMA4D is a potent pro-angiogenic molecule

  • SEMA4D binding to plexin-B1 on endothelial cells transactivates c-Met and promotes new blood vessel formation

  • Antibody-mediated neutralization of SEMA4D inhibits tumor angiogenesis and tumor growth in vivo

• Blocking tumor-promoting signaling:

  • SEMA4D binding to plexin-B1 on tumor cells results in c-Met transactivation and increased tumor cell migration

  • Overexpression of plexin-B1 and Met in breast and ovarian cancers is associated with worse grading and higher incidence of lymph node metastases

  • SEMA4D is produced by both tumor cells and tumor-associated macrophages

Importantly, Evans et al. demonstrated anti-SEMA4D-mediated tumor rejection in several murine tumor models, with increased efficacy when combined with checkpoint blockade inhibitors, corresponding with enhanced immune activity in the tumor microenvironment .

How does anti-SEMA4D antibody therapy differ from other immunomodulatory approaches in autoimmune and neurological disorders?

Anti-SEMA4D antibody therapy represents a novel therapeutic strategy with several distinguishing features compared to other immunomodulatory approaches in autoimmune and neurological disorders:

• Dual targeting of immune and CNS processes:

  • Unlike many immune-focused therapies, anti-SEMA4D approaches address both immunological and direct CNS mechanisms

  • SEMA4D knockout mice are resistant to experimental allergic encephalomyelitis (EAE, a murine model for multiple sclerosis)

  • Administration of anti-SEMA4D antibody attenuates EAE in multiple rodent models

• Preservation of broad immune function:

  • Unlike broad immunosuppressants, anti-SEMA4D therapy appears to have selective effects

  • Evaluation of anti-SEMA4D (VX15/2503) in a rat host resistance model showed it was not generally immunosuppressive, as it did not inhibit clearance of flu virus

  • The immune suppressive effects in vivo are much less pronounced than those reported for genetic deletion of SEMA4D in embryonic development

• Neuroreparative potential:

  • Beyond immunomodulation, SEMA4D inhibition may promote:

    • Oligodendrocyte survival

    • Remyelination

    • Preservation of the neurovascular unit by protecting endothelial tight junctions

  • This could reduce immune cell infiltration into the CNS and prevent activation of astrocytes and microglia, processes implicated in various neurodegenerative diseases

These differential characteristics position anti-SEMA4D therapy as a potential treatment for multiple sclerosis and other neuroinflammatory/neurodegenerative diseases with potential advantages over existing approaches.

What considerations should guide the selection of an appropriate isotype for therapeutic anti-SEMA4D antibodies?

The isotype selection for therapeutic anti-SEMA4D antibodies requires careful consideration of the intended mechanism of action and potential safety concerns:

• Effector function considerations:

  • For anti-SEMA4D therapy, depletion of SEMA4D-expressing immune cells is generally undesirable

  • Human IgG4 isotype was selected for VX15/2503 specifically to minimize potential depletion of SEMA4D-expressing immune cells

  • In vitro testing confirmed that VX15/2503 did not elicit complement-mediated cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) on SEMA4D-positive targets

• Structural stability concerns:

  • Human IgG4 antibodies are prone to form half-antibody structures due to flexibility in the hinge region

  • The S241P mutation in the hinge region is often introduced to "stabilize" IgG4 antibodies

  • VX15/2503 includes this mutation to prevent formation of half or bispecific antibodies

  • Testing in SCID mice confirmed that S241P-mutated VX15/2503 did not form bispecific antibodies in vivo

• Species cross-reactivity requirements:

  • For preclinical toxicology studies, antibodies that react with mouse, rat, primate, and human SEMA4D are advantageous

  • The humanized VX15/2503 maintained cross-reactivity with SEMA4D from multiple species

• Target engagement needs:

  • The selected isotype should maintain high affinity binding to SEMA4D

  • It should effectively block SEMA4D interactions with all three receptors (PLXNB1, PLXNB2, and CD72)

These considerations must be balanced to develop an antibody with optimal therapeutic properties while minimizing potential adverse effects.

What are the critical parameters for assessing the specificity and potential off-target effects of anti-SEMA4D antibodies?

Rigorous evaluation of specificity and potential off-target effects is crucial for anti-SEMA4D antibody development. Key assessment parameters include:

• Cross-reactivity assessment:

  • Binding specificity against a panel of irrelevant purified proteins by ELISA

  • Flow cytometry testing against cell lines known to be SEMA4D-negative

  • Tissue cross-reactivity studies using immunohistochemistry on normal human tissues

• Receptor blocking specificity:

  • Demonstration that antibody blocks SEMA4D binding to all three receptors (PLXNB1, PLXNB2, and CD72)

  • Quantitative potency determination for each receptor blocking activity

  • Confirmation that the antibody does not interfere with other receptor-ligand interactions beyond SEMA4D

• In vitro safety assessment:

  • CDC and ADCC assays to confirm absence of unwanted cell depletion

  • Cytokine release assays to assess potential immunostimulatory effects

  • Platelet activation studies (given SEMA4D expression on platelets)

• In vivo safety evaluation:

  • Toxicology studies in relevant species (enabled by cross-species reactivity)

  • Immunogenicity assessment

  • Host resistance models to evaluate impact on anti-pathogen responses

  • Assessment of potential impact on normal SEMA4D-dependent processes in the nervous and immune systems

These parameters help ensure that therapeutic anti-SEMA4D antibodies maintain target specificity while minimizing potential adverse effects, which is critical for both efficacy and safety in clinical applications.

What combinatorial approaches with anti-SEMA4D antibodies show the most promise in cancer immunotherapy?

Based on preclinical research, several combinatorial approaches with anti-SEMA4D antibodies show significant promise for enhancing cancer immunotherapy:

• Combination with immune checkpoint inhibitors:

  • Evans et al. demonstrated increased efficacy when anti-SEMA4D therapy was combined with checkpoint blockade inhibitors

  • This combination corresponded with enhanced immune activity in the tumor microenvironment

  • The mechanisms appear complementary: while checkpoint inhibitors release brakes on T-cell function, anti-SEMA4D antibodies may facilitate immune cell access to the tumor

• Integration with anti-angiogenic strategies:

  • SEMA4D functions as a potent pro-angiogenic factor through plexin-B1/c-Met signaling

  • Combining anti-SEMA4D with other anti-angiogenic approaches may provide synergistic inhibition of tumor vascularization

  • This could enhance drug delivery while reducing tumor growth and metastasis

• Combination with targeted therapies against c-Met:

  • Given that SEMA4D binding to plexin-B1 transactivates c-Met signaling in both endothelial and tumor cells

  • Combination with c-Met inhibitors might enhance anti-tumor efficacy

  • This approach could simultaneously target tumor cell migration and angiogenesis

• Incorporation into multimodal immunotherapy regimens:

  • As anti-SEMA4D treatment facilitates immune cell infiltration into tumors

  • Combination with immune activating agents (TLR agonists, cytokines, etc.) could potentially enhance anti-tumor responses

  • Sequential administration protocols might optimize efficacy

These combinatorial approaches highlight the potential for anti-SEMA4D antibodies to enhance existing cancer immunotherapies by addressing the immunosuppressive tumor microenvironment through complementary mechanisms.

What technological advances could improve the development and characterization of next-generation anti-semaphorin antibodies?

Several technological advances could significantly improve the development and characterization of next-generation anti-semaphorin antibodies:

• Advanced antibody engineering platforms:

  • Bispecific antibody formats to simultaneously target semaphorins and their receptors

  • Antibody-drug conjugates for targeted delivery of cytotoxic payloads to semaphorin-expressing cells

  • Site-specific conjugation technologies for improved homogeneity and stability

  • Novel Fc engineering to fine-tune effector functions and half-life

• High-resolution epitope mapping:

  • Cryo-electron microscopy to determine antibody-semaphorin complex structures

  • Hydrogen-deuterium exchange mass spectrometry for detailed epitope characterization

  • Computational modeling to predict and optimize antibody-antigen interactions

  • These approaches could enable the development of antibodies targeting specific functional domains of semaphorins

• Advanced functional screening systems:

  • High-content imaging platforms for multiplexed assessment of antibody effects

  • Organ-on-chip technologies for more physiologically relevant screening

  • Single-cell analysis techniques to characterize cellular heterogeneity in response to anti-semaphorin antibodies

  • AI/ML-driven predictive models for antibody optimization

• Improved in vivo models:

  • Humanized mouse models expressing human semaphorins and receptors

  • Patient-derived xenograft models for personalized efficacy assessment

  • Non-invasive imaging techniques to monitor antibody biodistribution and target engagement

These technological advances would enable more precise development and characterization of anti-semaphorin antibodies, potentially leading to improved therapeutic efficacy and reduced off-target effects in clinical applications.